An observational study in Sleep Apnea, Obstructive and Insomnia, sponsored by Lena Xiao. Recruiting at 1 site in Canada. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by Lena Xiao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Sleep Apnea, Obstructive with a site in Canada — 22 open to participants now, 31 under way, 4 of them phase 3. Sleep Apnea, Obstructive · Canada.
Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, this one is the 18th largest by planned enrollment of the 31 observational ones that give a count, is one of 10 that started in 2025, is one of 31 observational ones, reaches primary completion later than 11 of the 30 other live ones, and was the 126th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →22 of the 133 studies in Sleep Apnea, Obstructive with a site in Canada are open now. Recruiting first, the newest first:
The Hospital for Sick Children · Sites in Canada
Ages 2–18
Eli Lilly and Company · Sites in Canada, United States, Australia and 8 more countries
Ages 18+
University of British Columbia · Sites in Canada
Ages 19+ · Healthy volunteers
University of Alberta · Sites in Canada
Ages 18+
Lena Xiao · Sites in Canada
Ages 6–18
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 19 · Phase 4 7
First in 2003; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is below the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 60 across the 102 interventional studies, 100 across the 31 observational. Of the 86 that completed or were terminated, 10 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 133 have an industry lead sponsor. The 10 most frequent:
Lena Xiao is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Lena Xiao has 2 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
9 of the studies in Sleep Apnea, Obstructive with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT05678088Sunnybrook Health Sciences CentreOropharyngeal Exercises to Treat Obstructive Sleep Apnea | 2026-12 |
| NCT04187612Samuel Lunenfeld Research Institute, Mount Sinai HospitalAssociation of Body Fluid Distribution With Obstructive Sleep Apnea in Pregnant Women With Body Mass Index ≥ 40 kg/m2 | 2026-12 |
| NCT07301567University of British ColumbiaPilot Study of Negative Pressure Neck Therapy (NPNT) | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Positive Airway Pressure (PAP) is a treatment used to help people with sleep-disordered breathing, particularly those with obstructive sleep apnea (OSA). The device delivers pressurized air through a mask to keep the airways open during sleep, improving breathing and preventing interruptions in sleep.
Studying how insomnia affects PAP adherence in children can help improve future treatments.
However, no long-term studies have looked at this in children. Based on previous research, the investigators plan to conduct a study across multiple centers focusing on children with OSA starting PAP therapy. The study will explore how insomnia affects PAP adherence and how race and ethnicity play a role.
The first line of treatment for obstructive sleep apnea (OSA) is positive airway pressure (PAP) therapy, yet children have a less than 50% adherence rate, leaving many undertreated for this condition. Insomnia has been established as a modifiable risk factor for lowering PAP therapy adherence in adults with comorbid insomnia and sleep apnea (COMISA), and research has shown that treating insomnia with cognitive behavioural therapy for insomnia (CBTi) improved PAP adherence in adults. This is an important step forward for improving COMISA treatment outcomes, but cannot yet be applied to children without researching this relationship in paediatric populations. This study will address this research gap by conducting a thorough, in-depth evaluation of the association between paediatric COMISA and PAP adherence. The investigators aim to find whether a causal relationship exists between insomnia and PAP adherence in children with OSA, which has never been assessed longitudinally in children.
This multicenter study will be conducted at two tertiary care academic hospitals: The Hospital for Sick Children (Toronto, Canada) and British Columbia Children's Hospital (BCCH) (Vancouver, Canada). This study will include 82 participants from a diverse population to assess the association between race and ethnicity with PAP therapy adherence, based on previous research showing that being part of a self-identified minority is associated with lower PAP therapy adherence. Participants and caregivers will be asked to complete questionnaires regarding insomnia, sleep behaviour and quality of life at baseline prior to PAP therapy initiation. Electronic follow up questionnaires will be administered at 1, 2, and 3 months after PAP therapy initiation and PAP download data will be completed remotely. The primary objective of this study is to evaluate the impact of baseline insomnia on PAP therapy adherence at 3 months based on self-identified racial and ethnic minority. The results of this study will provide treatment insight and improvement to children with COMISA being treated with PAP therapy.
Participants will be recruited from two tertiary care academic hospitals, The Hospital for Sick Children (Toronto, Canada) and British Columbia Children's Hospital (BCCH) (Vancouver, Canada).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1) Developmental disability precluding ability to answer questionnaires
Children aged 8-18 years old diagnosed with obstructive sleep apnea (OSA) who are to be initiated on Positive Airway Pressure (PAP) therapy. Children and their caregivers must be willing and able to complete questionnaires about sleep as well as physical and mental health.
Device: Positive airway pressure therapy
Initiation of continuous or bilevel positive airway pressure therapy
Also known as: Continuous positive airway pressure therapy, Bilevel positive airway pressure therapy
Mean minutes of nightly PAP usage
Adherence will be determined objectively using ventilator download data (days 60-90 after PAP initiation)
Time frame: 90 days
Mean minutes of nightly PAP usage
Adherence will be determined objectively using ventilator download data (days 0-30 and 30-60 after PAP initiation)
Time frame: 30, 60 days
Self-Reported Sense of Mastery (Caregiver)
The self-reported Pearlin Mastery Scale will be used to measure the caregiver's mastery. Scores range from 7 to 28, with higher scores indicating greater levels of mastery.
Time frame: 0, 90 days
Self-Reported Sense of Mastery (Participant)
The self-reported Pearlin Mastery Scale will be used to measure the participant's individual mastery. Scores range from 7 to 28, with higher scores indicating greater levels of mastery.
Time frame: 0, 90 days
Self-Reported Psychological Scale (Percentage Rank)
The self-reported Psychological Scale from the KIDSCREEN-10 questionnaire will be used to measure health-related quality of life. The score ranges from 10-50, with lower scores indicating a "dissatisfaction with life".
Time frame: 0, 90 days
Self-Reported Psychological Scale
The self-reported Psychological Scale from the Strengths and Difficulties questionnaire will be used. Scores range from 0-50 with higher scores indicating more difficulties and lower scores indicating more strengths.
Time frame: 0, 90 days
Self-Reported Sleep Diary
The self-reported National Institutes of Health (NIH) 1-week Sleep Diary will be used to record the quality and quantity of sleep.
Time frame: 0, 90 days
Caregiver-Reported Insomnia Questionnaire
The caregiver-reported Pediatric Insomnia Severity Index will be used to measure the severity of pediatric insomnia symptoms. Scores range from 0 to 30, with higher scores indicating greater insomnia severity.
Time frame: 0, 90 days
Self-Reported Insomnia Questionnaire (Participant)
The self-reported Insomnia Severity Index will be used to measure the nature, severity and impact of the participant's insomnia. Scores range from 0 to 28, with higher scores indicating greater insomnia severity.
Time frame: 0, 30, 60, 90 days
Self-Reported Insomnia Questionnaire (Participant)
The self-reported Insomnia Severity Index will be used to diagnose insomnia in the participant. Children will be classified as having insomnia using a cut-off of ≥ 9 points, based on the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition.
Time frame: 0, 30, 60, 90 days
Self-Reported Insomnia Questionnaire (Caregiver)
The self-reported Insomnia Severity Index will be used to measure the nature, severity and impact of the caregiver's insomnia. Scores range from 0 to 28, with higher scores indicating greater insomnia severity.
Time frame: 0, 90 days
Self-Reported Insomnia Questionnaire (Caregiver)
The self-reported Insomnia Severity Index will be used to diagnose insomnia in the caregiver. Caregiver's will be classified as having insomnia using a cut-off of ≥ 9 points, based on the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition.
Time frame: 0, 90 days
Self-Reported Chronotype Questionnaire
The self-reported Munich Chronotype Questionnaire will be used to measure participant chronotype. Scores range from 16 to 86 with scores below 42 indicating "evening types", scores between 42-58 indicating "intermediate types" and scores above 58 indicating "morning types".
Time frame: 0, 90 days
Self-Reported Chronotype Questionnaire
The self-reported Morningness/Eveningness Questionnaire will be used to measure differences in activeness and alertness in the mornings and evenings. Scores range from 16 to 86, with lower scores representing evening preference and higher scores representing morning preference.
Time frame: 0, 90 days
Caregiver's Self-Reported Chronotype Questionnaire
The self-reported Morningness/Eveningness Questionnaire will be used to measure the caregiver's differences in activeness and alertness in the mornings and evenings. Scores range from 16 to 86, with lower scores representing evening preference and higher scores representing morning preference.
Time frame: 0, 90 days
Self-Reported Daytime Sleepiness Questionnaire
The self-reported Epworth Sleepiness Scale will be used to measure daytime sleepiness. Scores range from 0-24 with lower score indicating less daytime sleepiness.
Time frame: 0, 90 days
Self-Reported Caffeine Intake Questionnaire
The self-reported Caffeine Consumption Questionnaire-Revised will be used to measure weekly caffeine intake. The quantity and frequency of caffeinated products reported is used to estimate the average daily caffeine consumption in mg.
Time frame: 0, 90 days
Self-Reported Sleep Hygiene Questionnaire
The self-reported Adolescent Sleep Hygiene Scale (ASHS) will be used to assess sleep habits and hygiene practices. The 33-item scale contains 28 quantitative items, which are scored as the following: never (0%) = 1; once in a while (20%) = 2; sometimes (40%) = 3; quite often (60%) = 4; frequently, if not always (80%) = 5; always (100%) = 6. Total scores range from 28-168, with higher scores indicating greater sleep hygiene.
Time frame: 0, 90 days
Caregiver-Reported Global Rating Scale of Change
The caregiver-reported Global Rating Scale of Change will be used to measure the caregiver's perceived improvement or deterioration of the child's quality of life over time. The scale ranges from -7 to +7, with greater scores indicating improvements in quality of life.
Time frame: 90 days
Self-Reported Global Rating Scale of Change
The self-reported Global Rating Scale of Change will be used to measure the participant's perceived improvement or deterioration of their quality of life over time. The scale ranges from -7 to +7, with greater scores indicating improvements in quality of life.
Time frame: 90 days
Self-Reported PAP Adherence Questionnaire
The self-reported Adherence Barriers to CPAP Questionnaire will be used to estimate the participant's success or failure to use their PAP. The score ranges from 31 to 155, with greater scores indicating a higher number and severity of CPAP barriers.
Time frame: 90 days
Self-Reported Psychological (Total Anxiety) Subscale
The self-reported Total Anxiety Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-45, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.
Time frame: 0, 90 days
Self-Reported Psychological (Total Depression) Scale
The self-reported Total Depression (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-30, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.
Time frame: 0, 90 days
Self-Reported Psychological (Social Phobia) Scale
The self-reported Social Phobia Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-27, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.
Time frame: 0, 90 days
Self-Reported Psychological (Panic Disorder) Scale
The self-reported Panic Disorder Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-27, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.
Time frame: 0, 90 days
Self-Reported Psychological (Major Depression) Scale
The self-reported Major Depression Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-30, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.
Time frame: 0, 90 days
Self-Reported Psychological (Separation Anxiety) Scale
The self-reported Separation Anxiety Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-21, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.
Time frame: 0, 90 days
Self-Reported Psychological (Generalized Anxiety) Scale
The self-reported Generalized Anxiety Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-18, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.
Time frame: 0, 90 days
Self-Reported Psychological (Obsessive-Compulsive) Scale
The self-reported Obsessive-Compulsive Subscale (major outcome) from the Revised Child Anxiety and Depression Scale will be used. The raw score from the subscale, which ranges from 0-18, will be used to calculate the T score by taking into consideration development level and gender. A T score of 65 or higher indicates a score borderline the clinical threshold and a T score of 70 or higher indicates a score above the clinical threshold.
Time frame: 0, 90 days
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 18 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lena Xiao